Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

New England Journal of Medicine

Volumn 348, Issue 11, 2003, Pages 994-1004

  O'Brien, Stephen G ^a   Guilhot, François ^b   Larson, Richard A ^c   Gathmann, Insa ^d   Baccarani, Michele ^e   Cervantes, Francisco ^f   Cornelissen, Jan J ^g   Fischer, Thomas ^h   Hochhaus, Andreas ⁱ   Hughes, Timothy ^j   Lechner, Klaus ^k   Nielsen, Johan L ^l   Rousselot, Philippe ^m   Reiffers, Josy ⁿ   Saglio, Giuseppe ^o   Shepherd, John ^p   Simonsson, Bengt ^q   Gratwohl, Alois ^r   Goldman, John M ^s   Kantarjian, Hagop ^t   Taylor, Kerry ^u   Verhoef, Gregor ^v   Bolton, Ann E ^d   Capdeville, Renaud ^d   Druker, Brian J ^w   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF CHICAGO   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f HOSPITAL CLÍNIC   (Spain)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j ROYAL ADELAIDE HOSPITAL   (Australia)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ BORDEAUX UNIVERSITY HOSPITAL   (France)

^o SAN LUIGI GONZAGA HOSPITAL   (Italy)

^p VANCOUVER GENERAL HOSPITAL   (Canada)

^q UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^r UNIVERSITY HOSPITAL BASEL   (Switzerland)

^s HAMMERSMITH HOSPITAL   (United Kingdom)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u Mater Public Hospitals   (Australia)

^v UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^w OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; IMATINIB; PROTEIN TYROSINE KINASE; RECOMBINANT ALPHA INTERFERON;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BLAST CELL CRISIS; BLEEDING; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DEPRESSION; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METAPHASE; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PRURITUS; RASH; RHINOPHARYNGITIS; RIGOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; SURVIVAL RATE;

EID: 10744233716     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022457     Document Type: Article

References (36)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
3. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80.
4. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306:239-42.
5. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
6. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-4.
7. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
8. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247: 824-30.
9. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3.
10. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990;87:6649-53. [Erratum, Proc Natl Acad Sci U S A 1990;87:9072.]
11. Elefanty AG, Hariharan IK, Cory S. bcrabl, The hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9: 1069-78.
12. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-4.
13. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
14. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
15. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
16. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347: 481-7.
17. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440-8.
18. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289: 1938-42.
19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
20. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. [Erratum, N Engl J Med 2002;346:1923.]
21. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
22. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
23. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
24. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukaemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997;89:1616-20.
25. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-7.
26. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-5.
27. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-16.
28. Hehlmann P, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84:4064-77.
29. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 1998;91:2713-21.
30. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337: 223-9.
31. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
32. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25: 49-61.
33. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
36. Gratwohl A, Baldomero H, Urbano-Ispizua A. Transplantation in chronic myeloid leukaemia. Lancet 2002;359:712-3.